Investor Overview

Stock Information
Loading data...

Shares outstanding

45,939,509 (as of 03/21/2024)

Press Releases
Apr 18, 2024

-- Application allowed with broad method claims that are Orange Book-listable -- -- Once issued, this will be Evofem's fifth patent covering Hormone-Free "In the Moment" Contraceptive Phexxi in...

Mar 27, 2024

-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the...

Mar 20, 2024

— Medi-Cal serves more than 15.4 million Californians — — 7.4% improvement in Phexxi rebate to take effect July 1, 2024 — SAN DIEGO, March 20, 2024 /PRNewswire/ -- Commercial-stage women's...

Mar 7, 2024

-- New weight loss drugs like Ozempic, Wegovy and Zepbound may make oral birth control pills less effective at certain points -- SAN DIEGO, March 7, 2024 /PRNewswire/ -- Use of GLP-1 receptor...

Feb 1, 2024

Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth Total Operating Expense Reduced More Than 60% from 2022 Levels SAN DIEGO, Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc....

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at  

The U.S. contraceptive market was estimated at $8.3 billion as of 2022. Every 1% market share of the 43.3 million women in our addressable market represents more than $300 million in net product sales for Evofem.

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. The product is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.

Effective October 3, 2022, the Company's common stock trades on the OTCQB Venture Market under the ticker symbol "EVFM". From May 18, 2023, until June 20, 2023, it traded under the ticker symbol "EVFMD," then reverted to the ticker symbol "EVFM".

Featured Event
Tuesday, March 26, 2024
07:30 pm - 08:30 pm CDT

Join PALH and Mitch Rosen, Director of Sales Strategy and National Business Initiatives of Evofem Biosciences, to learn about non-hormonal, non-systemic contraception options.

View All

Latest Financial Results

Q4 and fiscal year ended December 31, 2023

Earnings Release
10-K Filing